ScreenerHero

QUIT Achieve Life Sciences, Inc.

NAS · US · Healthcare · Biotechnology · achievelifesciences.com
6.320USD+0.48%Mkt Cap: 651.61M USDP/E: —

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline…

Industry Peers

Biotechnology
Screen all Biotechnology
VRTX
Vertex Pharmaceuticals Incorporated
$136.56BUSDP/E 34.7
REGN
Regeneron Pharmaceuticals, Inc.
$98.84BUSDP/E 21.1
MRNA
Moderna, Inc.
$90.38BUSD
CSL
CSL Limited
$66.07BUSD
UCB
UCB SA
$62.48BUSDP/E 26.2
ARGX
argenx SE
$61.05BUSDP/E 35.3
ARGX
argenx SE
$60.37BUSDP/E 33.3
ONC
BeOne Medicines AG
$47.58BUSDP/E 53.4
RPRX
Royalty Pharma plc
$39.85BUSDP/E 45.3
RVMD
Revolution Medicines, Inc.
$37.27BUSD
GMAB
Genmab A/S
$31.67BUSDP/E 43.9
GMAB
Genmab A/S
$31.43BUSDP/E 45.8
ROIV
Roivant Sciences Ltd.
$28.64BUSD
INSM
Insmed Incorporated
$26.58BUSD
INCY
Incyte Corporation
$24.66BUSDP/E 61.7
ALNY
Alnylam Pharmaceuticals, Inc.
$22.11BUSDP/E 8.3
BNTX
BioNTech SE
$21.22BUSD
ASND
Ascendis Pharma A/S
$18.12BUSDP/E 18.1
EXEL
Exelixis, Inc.
$16.84BUSDP/E 20.7
JAZZ
Jazz Pharmaceuticals plc
$15.50BUSDP/E 71.5
Institutional holders20 on file

Key Statistics

Company
Market Cap651.61M USD
Enterprise Value522.25M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-111.71M USD
Revenue/Share—
Last Price6.320 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees28
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-9.24
PEG17.68
EV/EBITDA-8.18
EV/Revenue—
P/S—
P/B3.84
EPS (TTM)-1.71 USD
EPS (Forward)-0.68 USD
52W Range
5.93046% of range6.780
52W High6.780 USD
52W Low5.930 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-104.23%
ROA-31.01%
ROIC—
ROCE—
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-44.04M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-4.40%
Net Debt-187.47M USD
Net Debt/EBITDA2.93
Net Debt/FCF—
Balance Sheet
Debt/Equity7.77
Current Ratio10.49
Quick Ratio10.39
Book Value/Sh1.65 USD
Cash/Share1.83 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateJul 31, 2020
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)14.58 USD
Upside (mean)+130.7%
Target Range10.00 USD – 21.00 USD
10.00+130.7% to mean21.00
# Analysts12
Ownership
Shares Out.103.10M
Float79.87M
Insiders0.91%
Institutions83.80%
Short Interest
Short Ratio12.2d
Short % Float17.37%
Short % Out.17.27%
Shares Short17.81M
Short (prev mo.)15.99M
Technical
SMA 507.173 (-11.9%)
SMA 2005.700 (+10.9%)
Beta—
S&P 52W Chg12.75%
Avg Vol (30d)843.40K
Avg Vol (10d)1.18M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—

About Achieve Life Sciences (NASDAQ: QUIT)

›

Achieve Life Sciences (NASDAQ: QUIT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 28 employees.

The shares were at 6.320 USD on 13 November 2026. Its 52-week range is 5.930 USD to 6.780 USD: the price is 6.8% below the high and 6.6% above the low.

Its market capitalisation is 651.61M USD.

Achieve Life Sciences reports return on equity of -104.2% and an operating margin of 0.0%.

It holds more cash than debt, a net cash position of 187.47M USD. 12 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 14.58 USD is 130.7% above the current price. The next earnings report is expected on 23 March 2027.

Compare QUIT with VRTX and REGN →